Hyperion DeFi (NASDAQ:HYPD) Posts Earnings Results

Hyperion DeFi (NASDAQ:HYPD) issued its quarterly earnings data on Friday. The company reported $0.05 earnings per share for the quarter, Zacks reports. The company had revenue of $0.36 million for the quarter. Hyperion DeFi had a negative return on equity of 525.89% and a negative net margin of 62,238.41%.

Hyperion DeFi Stock Performance

Shares of HYPD traded up $0.04 during trading hours on Friday, reaching $5.01. 298,614 shares of the company traded hands, compared to its average volume of 462,523. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.20. The business has a fifty day moving average price of $8.52 and a 200-day moving average price of $7.08. Hyperion DeFi has a 12-month low of $0.85 and a 12-month high of $17.99. The stock has a market capitalization of $34.87 million, a P/E ratio of -0.20 and a beta of 2.57.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Wall Street Zen cut shares of Hyperion DeFi from a “hold” rating to a “sell” rating in a research report on Saturday, July 26th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $2.00.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.